Mechanism of STING Signaling and Auto-Activation during Pediatric Inflammatory Disease
The
cellular receptor STING (Stimulator of Interferon Genes) controls a human immunity
pathway that allows cells to sense pathogen- and tumor-derived DNA.
Uncontrolled activation of STING signaling has emerged as a direct cause of
childhood autoimmunity. STING-Associated Vasculopathy with onset in Infancy
(SAVI) is a rare disease caused by gain-of-function mutations in the receptor
that induce constitutive signaling and systemic immune activation. Children
with SAVI exhibit chronic inflammation, severe necrotizing vasculitis, and
neurological impairment. Specific therapies for SAVI disease do not currently
exist, and afflicted children rarely survive past childhood. Importantly, the
lack of insight into the function of SAVI mutations limits treatment, and demonstrates
that our current models of STING signaling are incomplete.
In
spite of the clear role of STING activation in immune cell responses, STING
signaling is poorly understood, including a gap in knowledge of how the
receptor engages downstream factors to initiate signaling. I have used a
biochemical and structural approach to understand STING activation, and my lab
is now uniquely poised to determine how patient mutations cause disease. All
SAVI mutations map within the receptor dimeric interface, and we hypothesize that
these mutations artificially “lock” an active signaling conformation.
To
test this model, we will use a genetic approach to define the protein
interaction motifs required for STING to recruit downstream signaling kinases
(Aim 1). Additionally, we will determine the structural impact of SAVI
mutations on STING conformation and biochemically define how mutations disrupt
regulation of kinase recruitment (Aim 2). The long-term goal of my lab is to
understand how STING signaling can be manipulated to rationally tune human
immune responses. Identifying the function of SAVI mutations will provide a
unique framework to develop a new model of STING activation, and offer the
opportunity to discover treatments that mitigate childhood autoimmunity
disease.